Campbell et al., showed that 1,25(OH)2D induced the expression of BRCA1 mRNA in the vitamin D-sensitive breast cancer cell line MCF-7, but not in their vitamin D-resistant counterpart MDA-MB-436 [126]. On screening several vitamin D-sensitive and -resistant breast cancer cell lines, these authors suggested that the sensitivity to the antiproliferative action of 1,25(OH)2D was strongly associated with its ability to modulate BRCA1. Moreover, vitamin D sensitivity correlated with ER expression. Therefore, VDR may induce factors that transactivate the BRCA1 gene and its expression mediates the antiproliferative effect of 1,25(OH)2D, but this pathway may be disrupted in breast cancer by pathogenically mutated BRCA1 or/and aberrant VDR signaling. In turn, Graziano et al., showed that RAS-induced senescence in human immortalized cell lines was associated with the downregulation of VDR and the vitamin D/VDR axis regulated the expression of the BRCA1 gene [127].Cysteine proteases are proteolytic enzymes that promote cancer invasion and metastasis as they degrade basement membrane and extracellular matrix. Cathepsin L (CTSL) is likely the most widely studied enzyme of this group and it is targeted in anti-metastatic therapy [128]. It is also important for the angiogenesis required by both primary and metastatic tumors [129]. Moreover, CTSL can contribute to surface characteristics of cancer cells, which can be important in distinguishing cancer cells from their normal counterparts [130]. However, it was also shown that CTSL might be involved in the regulation of cell cycle progression through proteolytic processing of the cut-like homeobox 1 (CUX-1) transcription factor [131,132].Burton et al., showed that CTSL, along with its downstream substrate CUX1, were overexpressed in samples from TNBC patients and TNBC cell lines in comparison to their ER-positive counterparts [133]. The inhibition of CUX1 in various TNBC cell lines by a CTSL inhibitor decreased the migration and invasiveness of these cells. Muscadine grape skin extract (MSKE) inhibited CUX1 expression, decreased its binding to the promoter of the ER-α gene and restored the expression of ER-α in the TNBC MDA-MB-468 cells. Both MSKE and CUX1 siRNAs restored the sensitivity of these cells to estradiol and 4-hydroxytamoxifen. Therefore, CTSL signaling can be involved in TNBC pathogenesis through CUX1 activation and CTSL and CUX1 may be targeted in TNBC therapy.Germline mutations in the BRCA1 gene occurring in breast cancer cases often result in a complete loss of function of BRCA1 [134,135]. In turn, BRCA1 loss is synthetically viable with the loss of tumor protein p53-binding protein 1 (TP53BP1) [136]. Both proteins are decisive in DNA double-strand break repair (DSBR) choice—BRCA1 promotes homologous recombination repair (HRR), whereas TP53BP1 promotes non-homologous end joining (NHEJ), although these relationships may change over time [137]. In general, the loss of TP53BP1 is associated with a worse prognosis in breast cancer and consequently TP53BP1 is considered as a tumor suppressor [138]. Gonzalo’s lab demonstrated that 1,25(OH)2D stabilized TP53BP1 via its interaction with VDR and promoted DSBR through the inhibition of CTSL,which is important in cancer progression and is involved in TP53BP1 degradation [139]. This effect might be mediated by endogenous inhibitors of cathepsins, as it was shown that 1,25(OH)2D upregulated cystatin D, which inhibited cathepsin D in the colorectal cancer cell line [140]. The upregulation of CTSL and its accumulation in the nucleus were found to be associated with the loss of A-type lamins [139]. However, such a loss resulted in a decrease in BRCA1 and RAD51 on both mRNA and protein levels [141]. Therefore, it could be speculated that 1,25(OH)2D and cathepsin inhibitors might rescue the levels of BRCA1 and RAD51, an assumption that was supported by the observations that 1,25(OH)2D reduced the basal level of DNA damage, the morphological defect characteristics of A-type lamins and the VDR-mediated expression of the BRCA1 gene [126]. The experiments in Gonzalo’s lab showed that 1,25(OH)2D rescued the levels of TP53BP1 and its ability to localize at the site of damaged DNA, as well as an important role of 1,25(OH)2D in the regulation of the two main DSB repair pathways, HRR and NHEJ [142] (Figure 2).
Campbell等人表明,1,25(OH)2D诱导了对维生素D敏感的乳腺癌细胞MCF-7中BRCA1 mRNA的表达,但没有诱导对维生素D耐药的对应物MDA-MB-436 [126] ]。在筛选几种对维生素D敏感和耐药的乳腺癌细胞系时,这些作者建议,对1,25(OH)2D的抗增殖作用的敏感性与其调节BRCA1的能力密切相关。此外,维生素D敏感性与ER表达相关。因此,VDR可能会诱导激活BRCA1基因的因子,其表达介导1,25(OH)2D的抗增殖作用,但是在乳腺癌中,该途径可能会因致病性突变的BRCA1或/和异常的VDR信号传导而中断。反过来,Graziano等人,<br>半胱氨酸蛋白酶是蛋白水解酶,可降解基底膜和细胞外基质,从而促进癌症的侵袭和转移。组织蛋白酶L(CTSL)可能是该组中研究最广泛的酶,并且靶向抗转移疗法[128]。对于原发性和转移性肿瘤都需要的血管生成也很重要[129]。而且,CTSL可以促进癌细胞的表面特性,这对于区分癌细胞与正常癌细胞是重要的[130]。然而,还显示CTSL可能通过切割样的同源盒1(CUX-1)转录因子的蛋白水解过程参与细胞周期进程的调控[131,132]。<br>Burton等人表明,与ER阳性对应物相比,来自TNBC患者和TNBC细胞系的样品中CTSL及其下游底物CUX1过表达。CTSL抑制剂对各种TNBC细胞系中CUX1的抑制作用降低了这些细胞的迁移和侵袭性。麝香葡萄皮提取物(MSKE)抑制TNBC MDA-MB-468细胞中CUX1的表达,降低其与ER-α基因启动子的结合并恢复ER-α的表达。MSKE和CUX1 siRNA均可恢复这些细胞对雌二醇和4-羟基他莫昔芬的敏感性。因此,CTSL信号传导可通过CUX1激活而参与TNBC发病机理,而CTSL和CUX1可能是TNBC治疗的靶标。<br>在乳腺癌病例中发生的BRCA1基因的种系突变通常会导致BRCA1的功能完全丧失[134,135]。反过来,BRCA1的丧失与肿瘤蛋白p53结合蛋白1(TP53BP1)的丧失在合成上是可行的[136]。两种蛋白质在DNA双链断裂修复(DSBR)选择中起决定性作用-BRCA1促进同源重组修复(HRR),而TP53BP1促进非同源末端连接(NHEJ),尽管这些关系可能随时间而改变[137]。通常,TP53BP1的丢失与乳腺癌的预后较差有关,因此TP53BP1被认为是一种肿瘤抑制因子[138]。Gonzalo的实验室证明1,25(OH)2D通过与VDR相互作用稳定了TP53BP1,并通过抑制CTSL促进了DSBR,<br>这在癌症进展中很重要,并且与TP53BP1降解有关[139]。这种作用可能是由组织蛋白酶的内源性抑制剂介导的,因为已证明1,25(OH)2D上调了胱抑素D,从而抑制了结直肠癌细胞系中的组织蛋白酶D [140]。发现CTSL的上调及其在细胞核中的积累与A型核纤层蛋白的丢失有关[139]。但是,这样的损失导致BRCA1和RAD51的mRNA和蛋白质水平降低[141]。因此,可以推测1,25(OH)2D和组织蛋白酶抑制剂可以挽救BRCA1和RAD51的水平,这一假设得到了1,25(OH)2D降低基础DNA损伤水平的观察结果的支持, A型lamin的形态缺陷特征和BRCA1基因的VDR介导表达[126]。
正在翻译中..
Campbell et al., showed that 1,25(OH)2D induced the expression of BRCA1 mRNA in the vitamin D-sensitive breast cancer cell line MCF-7, but not in their vitamin D-resistant counterpart MDA-MB-436 [126]. On screening several vitamin D-sensitive and -resistant breast cancer cell lines, these authors suggested that the sensitivity to the antiproliferative action of 1,25(OH)2D was strongly associated with its ability to modulate BRCA1. Moreover, vitamin D sensitivity correlated with ER expression. Therefore, VDR may induce factors that transactivate the BRCA1 gene and its expression mediates the antiproliferative effect of 1,25(OH)2D, but this pathway may be disrupted in breast cancer by pathogenically mutated BRCA1 or/and aberrant VDR signaling. In turn, Graziano et al., showed that RAS-induced senescence in human immortalized cell lines was associated with the downregulation of VDR and the vitamin D/VDR axis regulated the expression of the BRCA1 gene [127].<br>Cysteine proteases are proteolytic enzymes that promote cancer invasion and metastasis as they degrade basement membrane and extracellular matrix. Cathepsin L (CTSL) is likely the most widely studied enzyme of this group and it is targeted in anti-metastatic therapy [128]. It is also important for the angiogenesis required by both primary and metastatic tumors [129]. Moreover, CTSL can contribute to surface characteristics of cancer cells, which can be important in distinguishing cancer cells from their normal counterparts [130]. However, it was also shown that CTSL might be involved in the regulation of cell cycle progression through proteolytic processing of the cut-like homeobox 1 (CUX-1) transcription factor [131,132].<br>Burton et al., showed that CTSL, along with its downstream substrate CUX1, were overexpressed in samples from TNBC patients and TNBC cell lines in comparison to their ER-positive counterparts [133]. The inhibition of CUX1 in various TNBC cell lines by a CTSL inhibitor decreased the migration and invasiveness of these cells. Muscadine grape skin extract (MSKE) inhibited CUX1 expression, decreased its binding to the promoter of the ER-α gene and restored the expression of ER-α in the TNBC MDA-MB-468 cells. Both MSKE and CUX1 siRNAs restored the sensitivity of these cells to estradiol and 4-hydroxytamoxifen. Therefore, CTSL signaling can be involved in TNBC pathogenesis through CUX1 activation and CTSL and CUX1 may be targeted in TNBC therapy.<br>Germline mutations in the BRCA1 gene occurring in breast cancer cases often result in a complete loss of function of BRCA1 [134,135]. In turn, BRCA1 loss is synthetically viable with the loss of tumor protein p53-binding protein 1 (TP53BP1) [136]. Both proteins are decisive in DNA double-strand break repair (DSBR) choice—BRCA1 promotes homologous recombination repair (HRR), whereas TP53BP1 promotes non-homologous end joining (NHEJ), although these relationships may change over time [137]. In general, the loss of TP53BP1 is associated with a
正在翻译中..
Campbell等人表明,1,25(OH)2D诱导维生素D敏感乳腺癌细胞系MCF-7中BRCA1 mRNA的表达,但不诱导其维生素D抗性对应物MDA-MB-436的表达[126]。在筛选几种维生素D敏感和耐药的乳腺癌细胞系时,作者认为1,25(OH)2D抗增殖作用的敏感性与其调节BRCA1的能力密切相关。此外,维生素D敏感性与ER表达相关。因此,VDR可能诱导反式激活BRCA1基因的因子,其表达介导1,25(OH)2D的抗增殖作用,但在乳腺癌中,这一途径可能被致病性突变的BRCA1或/和异常VDR信号传导阻断。反过来,Graziano等人指出,RAS诱导的人类永生细胞系的衰老与VDR的下调有关,维生素D/VDR轴调节BRCA1基因的表达[127]。<br>半胱氨酸蛋白酶是一种蛋白水解酶,在降解基底膜和细胞外基质的同时促进肿瘤的侵袭和转移。组织蛋白酶L(CTSL)可能是这一组中研究最广泛的酶,它是抗转移治疗的靶点[128]。对于原发性和转移性肿瘤所需的血管生成也很重要[129]。此外,CTSL还可以对癌细胞的表面特征做出贡献,这对于区分癌细胞与正常细胞具有重要意义[130]。然而,也有研究表明,CTSL可能通过切割样同源框1(CUX-1)转录因子的蛋白水解过程参与细胞周期进程的调节[131132]。<br>Burton等人表明,与ER阳性对应物相比,CTSL及其下游底物CUX1在TNBC患者和TNBC细胞系的样本中过度表达[133]。CTSL抑制剂对不同TNBC细胞株CUX1的抑制作用降低了这些细胞的迁移和侵袭力。麝香草定葡萄皮提取物(MSKE)抑制CUX1的表达,降低其与ER-α基因启动子的结合,恢复ER-α在TNBC-MDA-MB-468细胞中的表达。MSKE和CUX1 sirna均恢复了这些细胞对雌二醇和4-羟基三苯氧胺的敏感性。因此,CTSL信号可以通过CUX1的激活参与TNBC的发病机制,CTSL和CUX1可能是TNBC治疗的靶向药物。<br>乳腺癌患者BRCA1基因的种系突变通常导致BRCA1功能完全丧失[134135]。反过来,BRCA1的缺失与肿瘤蛋白p53结合蛋白1(TP53BP1)的丢失在合成上是可行的[136]。这两种蛋白质在DNA双链断裂修复(DSBR)选择中起决定性作用——BRCA1促进同源重组修复(HRR),而TP53BP1促进非同源末端连接(NHEJ),尽管这些关系可能会随着时间而改变[137]。总的来说,TP53BP1的丢失与乳腺癌预后差有关,因此TP53BP1被认为是一种肿瘤抑制因子[138]。冈萨洛的实验室证明,1,25(OH)2D通过与VDR的相互作用稳定TP53BP1,并通过抑制CTSL促进DSBR,<br>它在癌症进展中很重要,并参与TP53BP1降解[139]。这种作用可能是由组织蛋白酶的内源性抑制剂介导的,因为1,25(OH)2D上调了胱抑素D,它抑制了结直肠癌细胞系中的组织蛋白酶D[140]。CTSL的上调及其在细胞核中的积聚被发现与A型椎板的丢失有关[139]。然而,这种缺失导致BRCA1和RAD51在mRNA和蛋白质水平上的降低[141]。因此,可以推测1,25(OH)2D和组织蛋白酶抑制剂可以挽救BRCA1和RAD51的水平,这一假设得到了观察结果的支持,即1,25(OH)2D降低了DNA损伤的基础水平、A型层粘连的形态缺陷特征和VDR介导的BRCA1基因的表达[126]。冈萨罗实验室的实验表明,1,25(OH)2D可挽救TP53BP1的水平及其在受损DNA位置定位的能力,以及1,25(OH)2D在调节两个主要DSB修复途径HRR和NHEJ中的重要作用[142](图2)。<br>
正在翻译中..